02-Jul-2026 13:52:37

AJANTA PHARMA : UPDATE ON US FDA INSPECTION AT PAITHAN MANUFACTURING FACILITY

• The company received the Establishment Inspection Report (EIR) from the USFDA for its Paithan manufacturing facility. • The inspection has been classified as Voluntary Action Indicated (VAI). • The cGMP inspection was conducted from April 13, 2026, to April 21, 2026. • The company had previously informed the stock exchanges about the inspection on April 22, 2026. Impact: Neutral (Routine update on FDA inspection classification)

Ajanta Pharma Ltd

← Back to feed